India, Feb. 24 -- Acurx Pharmaceuticals, Inc. (ACXP) Monday announced that its lead antibiotic candidate, ibezapolstat, is advancing to international Phase 3 clinical trials for treating C. difficile Infection.
A recent study published in the Journal of Antimicrobial Agents and Chemotherapeutics highlights ibezapolstat's ability to preserve beneficial gut bacteria, unlike vancomycin, which is linked to higher C. difficile recurrence.
The study found that genomic differences in PolC-type DNA Polymerase III allow beneficial microbes to resist ibezapolstat, supporting gut health.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
Acurx plans to leverage these findings to advance its systemic Gram-positive ...